Chengdu New Radiomedicine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A developer of targeted radiopharmaceuticals for precise cancer diagnosis and treatment.

OncologyDiagnostics

A radiopharmaceutical platform for conjugating targeting molecules with therapeutic and diagnostic radioisotopes to enable precision oncology.

Riding the wave of theranostics, a promising field that combines diagnosis and treatment to personalize cancer care.

Faces complex logistics in radioisotope supply chain, stringent radiation safety regulations, and clinical trial challenges.

Enters a competitive but high-growth market dominated by global players like Novartis, but with significant local demand in China.